Register entryShortage reported
Bristol Myers Squibb Company
- Registered sites
- 8
- Drug products
- 4
- Live patents
- 167
- Countries
- 4
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingActive ingredient (API) manufactureLabellingFinished drug manufacturePackaging
Sites
Facilities
8| Site | Location | Operations | FEI |
|---|---|---|---|
| Celgene International Sarl | BoudrySwitzerland | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3006323509 |
| Bristol-Myers Squibb Pharmaceuticals Limited | MoretonUnited Kingdom | Analytical testing | 3002806602 |
| Swords Laboratories Unlimited Company | MulhuddartIreland | Analytical testing, Active ingredient (API) manufacture | 3004531790 |
| Juno Therapeutics, Inc. | Bothell, WAUnited States | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3011834594 |
| Bristol-Myers Squibb Company | Devens, MAUnited States | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3008455069 |
| Bristol-Myers Squibb Holdings Pharma, Ltd. Liability Company | Manati, PRUnited States | Analytical testing, Labelling, Finished drug manufacture, Packaging | 2650089 |
| CELGENE CORPORATION | SUMMIT, NJUnited States | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3004991673 |
| Juno Therapeutics, Inc. | Seattle, WAUnited States | Analytical testing | 3010932912 |
Alert
Products in shortage
1| Drug | Presentation | Availability |
|---|---|---|
| Azacitidine Injection | Vidaza, Injection, 100 mg (NDC 59572-102-01) | Available |
Exclusivity
Patents
167Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| ABRAXANE | PACLITAXEL | Aug 2026 |
| ABRAXANE | PACLITAXEL | Feb 2027 |
| ABRAXANE | PACLITAXEL | Mar 2032 |
| ABRAXANE | PACLITAXEL | Sept 2032 |
| ABRAXANE | PACLITAXEL | Jan 2034 |
| ABRAXANE | PACLITAXEL | Jul 2034 |
| AUGTYRO | REPOTRECTINIB | Jan 2035 |
| AUGTYRO | REPOTRECTINIB | Jul 2036 |
| AUGTYRO | REPOTRECTINIB | Jul 2036 |
| AUGTYRO | REPOTRECTINIB | Jul 2036 |
| CAMZYOS | MAVACAMTEN | Jun 2034 |
| CAMZYOS | MAVACAMTEN | Apr 2036 |
| COBENFY | TROSPIUM CHLORIDE; XANOMELINE TARTRATE | Jul 2030 |
| COBENFY | TROSPIUM CHLORIDE; XANOMELINE TARTRATE | Sept 2039 |
| COBENFY | TROSPIUM CHLORIDE; XANOMELINE TARTRATE | Oct 2039 |
| DAKLINZA | DACLATASVIR DIHYDROCHLORIDE | Aug 2027 |
| DAKLINZA | DACLATASVIR DIHYDROCHLORIDE | Aug 2027 |
| DAKLINZA | DACLATASVIR DIHYDROCHLORIDE | Jul 2029 |
| DAKLINZA | DACLATASVIR DIHYDROCHLORIDE | Jun 2031 |
| ELIQUIS SPRINKLE | APIXABAN | Nov 2026 |
| ELIQUIS SPRINKLE | APIXABAN | May 2027 |
| ELIQUIS SPRINKLE | APIXABAN | Nov 2040 |
| ELIQUIS SPRINKLE | APIXABAN | May 2041 |
| EVOTAZ | ATAZANAVIR SULFATE; COBICISTAT | Sept 2029 |
| EVOTAZ | ATAZANAVIR SULFATE; COBICISTAT | Oct 2032 |
| IDHIFA | ENASIDENIB MESYLATE | Jun 2030 |
| IDHIFA | ENASIDENIB MESYLATE | Jan 2033 |
| IDHIFA | ENASIDENIB MESYLATE | Aug 2034 |
| IDHIFA | ENASIDENIB MESYLATE | Sept 2034 |
| INREBIC | FEDRATINIB HYDROCHLORIDE | Dec 2026 |
| INREBIC | FEDRATINIB HYDROCHLORIDE | Jun 2028 |
| INREBIC | FEDRATINIB HYDROCHLORIDE | Nov 2031 |
| INREBIC | FEDRATINIB HYDROCHLORIDE | Jun 2032 |
| INREBIC | FEDRATINIB HYDROCHLORIDE | Sept 2039 |
| KRAZATI | ADAGRASIB | May 2037 |
| KRAZATI | ADAGRASIB | Feb 2041 |
| KRAZATI | ADAGRASIB | Sept 2041 |
| KRAZATI | ADAGRASIB | Aug 2043 |
| ONUREG | AZACITIDINE | May 2029 |
| ONUREG | AZACITIDINE | Jun 2030 |
| POMALYST | POMALIDOMIDE | May 2030 |
| POMALYST | POMALIDOMIDE | Nov 2030 |
| POMALYST | POMALIDOMIDE | Jun 2031 |
| POMALYST | POMALIDOMIDE | Dec 2031 |
| REVLIMID | LENALIDOMIDE | Apr 2027 |
| REVLIMID | LENALIDOMIDE | Mar 2028 |
| SOTYKTU | DEUCRAVACITINIB | Nov 2033 |
| SOTYKTU | DEUCRAVACITINIB | Feb 2043 |
| SPRYCEL | DASATINIB | Sept 2026 |
| ZEPOSIA | OZANIMOD HYDROCHLORIDE | May 2029 |
| ZEPOSIA | OZANIMOD HYDROCHLORIDE | Nov 2030 |
| ZEPOSIA | OZANIMOD HYDROCHLORIDE | Mar 2033 |
| ZEPOSIA | OZANIMOD HYDROCHLORIDE | Sept 2038 |
Catalogue
Marketed products
4Showing 4 of 4.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| - | NIVOLUMAB | INJECTION | BULK INGREDIENT |
| - | RELATLIMAB | INJECTION | BULK INGREDIENT |
| - | abatacept | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BULK INGREDIENT |
| - | elotuzumab | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BULK INGREDIENT |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.